Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kelly McQuarrie

Showing results (11-20 of 24) with videos related to

Pageof 3
Sort By:
Health and Quality of Life Outcomes|July 15, 2014
Assessment of sleep in patients with fibromyalgia: qualitative development of the fibromyalgia sleep diaryLeah Kleinman, Sally Mannix, Lesley M Arnold, et al.
Journal of Patient-Reported Outcomes|July 29, 2022
Development of a novel patient-reported outcome measure to assess signs and symptoms of COVID-19Carla Romano, Sheri Fehnel, Jeffrey Stoddard, et al.
Advances in Therapy|December 9, 2019
Matching-Adjusted Indirect Comparison of Health-Related Quality of Life and Adverse Events of Apalutamide Versus Enzalutamide in Non-Metastatic Castration-Resistant Prostate CancerSimon Chowdhury, Stéphane Oudard, Hiroji Uemura, et al.
BMC Infectious Diseases|November 1, 2025
A qualitative burden of disease study in patients with invasive Escherichia coli disease aged ≥ 60 years in the United StatesMark A Schmidt, Inga Gruß, James V Davis, et al.
Prostate Cancer|October 10, 2022
Randomized, Open-Label Phase 2 Study of Apalutamide plus Androgen Deprivation Therapy versus Apalutamide Monotherapy versus Androgen Deprivation Monotherapy in Patients with Biochemically Recurrent Prostate CancerRahul Aggarwal, Joshi J Alumkal, Russell Z Szmulewitz, et al.
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation|November 9, 2019
Does recall period matter? Comparing PROMIS<sup>®</sup> physical function with no recall, 24-hr recall, and 7-day recallDavid M Condon, Robert Chapman, Sara Shaunfield, et al.
JCO Oncology Practice|June 3, 2026
Participant-Reported Preference for Pembrolizumab Administered Subcutaneously or Intravenously: A Randomized, Open-Label, Phase II StudyIgnacio A Casarini, Dariusz M Kowalski, Christian Caglevic, et al.
The Lancet. Oncology|January 13, 2018
Patient-reported outcomes following abiraterone acetate plus prednisone added to androgen deprivation therapy in patients with newly diagnosed metastatic castration-naive prostate cancer (LATITUDE): an international, randomised phase 3 trialKim N Chi, Andrew Protheroe, Alfredo Rodríguez-Antolín, et al.
The Lancet. Oncology|September 15, 2018
Effect of apalutamide on health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: an analysis of the SPARTAN randomised, placebo-controlled, phase 3 trialFred Saad, David Cella, Ethan Basch, et al.
Journal of Patient-Reported Outcomes|May 17, 2023
Psychometric evaluation of the Symptoms of Infection with Coronavirus-19 (SIC): results from a cross-sectional study and a phase 3 clinical trialEric K H Chan, Valerie Williams, Carla Romano, et al.
Pageof 3

Showing results (11-20 of 24) with videos related to

Sort By:
Pageof 3
Health and Quality of Life Outcomes|July 15, 2014
Assessment of sleep in patients with fibromyalgia: qualitative development of the fibromyalgia sleep diaryLeah Kleinman, Sally Mannix, Lesley M Arnold, et al.
Journal of Patient-Reported Outcomes|July 29, 2022
Development of a novel patient-reported outcome measure to assess signs and symptoms of COVID-19Carla Romano, Sheri Fehnel, Jeffrey Stoddard, et al.
Advances in Therapy|December 9, 2019
Matching-Adjusted Indirect Comparison of Health-Related Quality of Life and Adverse Events of Apalutamide Versus Enzalutamide in Non-Metastatic Castration-Resistant Prostate CancerSimon Chowdhury, Stéphane Oudard, Hiroji Uemura, et al.
BMC Infectious Diseases|November 1, 2025
A qualitative burden of disease study in patients with invasive Escherichia coli disease aged ≥ 60 years in the United StatesMark A Schmidt, Inga Gruß, James V Davis, et al.
Prostate Cancer|October 10, 2022
Randomized, Open-Label Phase 2 Study of Apalutamide plus Androgen Deprivation Therapy versus Apalutamide Monotherapy versus Androgen Deprivation Monotherapy in Patients with Biochemically Recurrent Prostate CancerRahul Aggarwal, Joshi J Alumkal, Russell Z Szmulewitz, et al.
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation|November 9, 2019
Does recall period matter? Comparing PROMIS<sup>®</sup> physical function with no recall, 24-hr recall, and 7-day recallDavid M Condon, Robert Chapman, Sara Shaunfield, et al.
JCO Oncology Practice|June 3, 2026
Participant-Reported Preference for Pembrolizumab Administered Subcutaneously or Intravenously: A Randomized, Open-Label, Phase II StudyIgnacio A Casarini, Dariusz M Kowalski, Christian Caglevic, et al.
The Lancet. Oncology|January 13, 2018
Patient-reported outcomes following abiraterone acetate plus prednisone added to androgen deprivation therapy in patients with newly diagnosed metastatic castration-naive prostate cancer (LATITUDE): an international, randomised phase 3 trialKim N Chi, Andrew Protheroe, Alfredo Rodríguez-Antolín, et al.
The Lancet. Oncology|September 15, 2018
Effect of apalutamide on health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: an analysis of the SPARTAN randomised, placebo-controlled, phase 3 trialFred Saad, David Cella, Ethan Basch, et al.
Journal of Patient-Reported Outcomes|May 17, 2023
Psychometric evaluation of the Symptoms of Infection with Coronavirus-19 (SIC): results from a cross-sectional study and a phase 3 clinical trialEric K H Chan, Valerie Williams, Carla Romano, et al.
Pageof 3